Rage and Vascular Disease in Diabetes

Abstract

Funding Agency

Agency: National Institute of Health (NIH)
Institute: National Heart, Lung, and Blood Institute (NHLBI)
Type: Research Project (R01)
Project #: 5R01HL056881-03
Application #: 2809831
Study Section

Project Start: 1996-07-01
Project End: 2001-06-30
Budget Start: 1998-07-01
Budget End: 1999-06-30
Support Year: 3
Fiscal Year: 1998
Total Cost
Indirect Cost

Related projects


NIH 2000 R01 HL	Rage and Vascular Disease in Diabetes Ramasamy, Ravichandran / Columbia University (N.Y.)	$344,816
NIH 1999 R01 HL	Rage and Vascular Disease in Diabetes Stern, David M. / Columbia University (N.Y.)
NIH 1998 R01 HL	Rage and Vascular Disease in Diabetes Stern, David M. / Columbia University (N.Y.)
NIH 1998 R01 HL	Rage and Vascular Disease in Diabetes /
NIH 1997 R01 HL	Rage and Vascular Disease in Diabetes Stern, David M. / Columbia University (N.Y.)
NIH 1997 R01 HL	Rage and Vascular Disease in Diabetes Stern, David M. / Columbia University (N.Y.)
NIH 1996 R01 HL	Rage and Vascular Disease in Diabetes Stern, David M. / Columbia University (N.Y.)

Publications

Lue, L F; Walker, D G; Brachova, L et al. (2001) Involvement of microglial receptor for advanced glycation endproducts (RAGE) in Alzheimer's disease: identification of a cellular activation mechanism. Exp Neurol 171:29-45

Hofmann, M A; Drury, S; Fu, C et al. (1999) RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97:889-901

Kislinger, T; Fu, C; Huber, B et al. (1999) N(epsilon)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J Biol Chem 274:31740-9

Park, L; Raman, K G; Lee, K J et al. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat Med 4:1025-31

Comments

Be the first to comment on this grant